Tertiary lymphoid structures (TLS) are lymph node-like organizations of immune cells within inflamed tissues that can drive immune cell activation. TLS has been a hot topic in the field of immuno-oncology, where it is believed they play a critical role in influencing the tumor microenvironment. Since TLSs are associated with improvement in clinical outcomes, their presence or induction following cancer therapies could be a valuable predictor of therapeutic responses. Stop by our blog to find out how our team studies tertiary lymphoid structures – a promising biomarker for immunotherapy. https://bit.ly/3FmiS6O #TertiaryLymphoidStructures #Biomarker #Immunotherapy #SpatialBiology
Akoya Biosciences, Inc.’s Post
More Relevant Posts
-
Watch this on-demand Molecular Tumor Board, where presenters review tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. They provide an overview of risk factors, prognosis and biomarker-driven therapy selection, underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. #PrecisionOncology
Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion
learn-more.com
-
TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy - Cell Stress and Immunity Lab #AntiCancer #Immunotherapy #Chemotherapy #Oncology #Cancer #Research #OncoDaily
TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy -Cell Stress and Immunity Lab - OncoDaily
oncodaily.com
-
New!📌 Validation of a multiomic model of #plasmaextracellularvesicle PD-L1 and radiomics for prediction of response to #immunotherapy in NSCLC ----------------------------- Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. Here Christian Rolfo, MD, PhD, MBA,Dr.h.c. et al. showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response to ICIs. Look here⤵️ https://lnkd.in/dbEeYh6y #LungCancer #Immunecheckpointinhibitor #LiquidBiopsy IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano
-
-
Associate Researcher, Cancerfonden fellowship at Division of Translational Cancer Research, Lund University
I´m happy to share that our latest study is under review and can be found at BioRxiv. In this study we uncover the unanticipated expression of Activin receptor-like kinase 1 (ALK1) by immunosuppressive macrophage subset that has been linked to immunotherapy resistance and poor survival. Here, we show that ALK1 inhibition not only prevents the recruitment of immune-suppressive macrophages, but also redirects the differentiation trajectory of bone marrow- derived precursors away from this detrimental path. #ALK1 #Tumorbiology #TAMs #breastcancer #immunotherapy #Pietraslab https://lnkd.in/eaj89tQT https://lnkd.in/eHBRnrEn
KPietraslab (@KPietraslab) on X
x.com
-
Watch this on-demand Molecular Tumor Board, where presenters review tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. They provide an overview of risk factors, prognosis and biomarker-driven therapy selection, underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. #PrecisionOncology
Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion
learn-more.com
-
Watch this on-demand Molecular Tumor Board, where presenters review tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. They provide an overview of risk factors, prognosis and biomarker-driven therapy selection, underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. #PrecisionOncology
Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion
learn-more.com
-
Watch this on-demand Molecular Tumor Board, where presenters review tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. They provide an overview of risk factors, prognosis and biomarker-driven therapy selection, underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. #PrecisionOncology
Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion
learn-more.com
-
Watch this on-demand Molecular Tumor Board, where presenters review tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. They provide an overview of risk factors, prognosis and biomarker-driven therapy selection, underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. #PrecisionOncology
Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion
learn-more.com
-
Watch this on-demand Molecular Tumor Board, where presenters review tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. They provide an overview of risk factors, prognosis and biomarker-driven therapy selection, underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. #PrecisionOncology
Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion
learn-more.com
-
Watch this on-demand Molecular Tumor Board, where presenters review tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. They provide an overview of risk factors, prognosis and biomarker-driven therapy selection, underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. #PrecisionOncology
Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion
learn-more.com
